A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 31/7088 (2006.01) A61P 11/00 (2006.01)
Patent
CA 2682666
Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNF.alpha. antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.
L'invention concerne des procédés de traitement de troubles liés à l'activité de CXCL13 utilisant des antagonistes de CXCL13 et, facultativement, des antagonistes de TNFa, tels que des anticorps, y compris des portions ou variantes spécifiées, des polypeptides, des polynucléotides, de l'ARNsi, de l'ARNsh, des ribozymes et des ADNsymes. Des troubles liés à l'activité du CXCL13 comprennent des troubles inflammatoires, tels que des troubles pulmonaires, par exemple l'asthme, l'emphysème, et COPD, et le lupus érythémateux disséminé.
Bugelski Peter
Griswold Donald E.
Liang Bailin
Sarisky Robert T.
Bugelski Peter
Centocor Ortho Biotech Inc.
Griswold Donald E.
Liang Bailin
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Cxcl13 antagonists and their use for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cxcl13 antagonists and their use for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cxcl13 antagonists and their use for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1692214